June 13, 2006 – New diabetes offerings dominated the news, including candidates from Novartis, Merck, Isis and OSI that seem an advance over present therapies; Arena presented data on its weight-loss drug; Bayer and Onyx have been given Fast Track status for Nexavar as a liver cancer therapy; MyVax, the cancer vaccine from Genitope, was another winner of Fast Track designation, Pharmion completed the application for approval of an IV formulation of Vidaza; Discovery Partners sold its drug discovery operations to Galapagos to clean house before its reverse merger with Infinity; ViaCell signed a deal with Centocor to see whether the cord blood stem cells will treat cardiac disease; Cephalon entered into a deal to co-promote Provigil with Takeda Pharma in the US; and Amgen said the FDA accepted its filing for marketing approval of panitumumab. The Centient Biotech 200™ fell 35 points to 3555.29, a drop of .97%. More details...
